ARTICLE | Emerging Company Profile
Neurogene: Genes over ERT for monogenic CNS diseases
Why Neurogene is developing gene therapies for two monogenic CNS diseases
March 15, 2019 11:20 PM UTC
Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored.
Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations that lead to toxic accumulation of N-acetylglucosamines and cellular dysfunction in multiple tissue and cell types, including neurons. The disease is characterized by development delay and intellectual disability as well as psychomotor regression. ...
BCIQ Company Profiles